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Abstract
Background: Obesity has been associated with poor oncologic outcomes following pancreatoduo-
denectomy for pancreatic cancer. However, there is a paucity of evidence on the impact of obesity on
postoperative complications, oncologic outcome and survival in patients with hepatocellular carcinoma
(HCC) undergoing orthotopic liver transplantation (OLT).
Methods: From a database of over 1000 patients who underwent OLT during 1996–2008, 159 patients
with a diagnosis of HCC were identified. Demographic data, body mass index (BMI), perioperative
parameters, recurrence and survival were obtained. Complications were grouped according to Clavien–
Dindo grading (Grades I–V).
Results: There were increased incidences of life-threatening complications in overweight (58%) and
obese (70%) patients compared with the non-obese patient group (41%) (P < 0.05). Furthermore, the
incidence of recurrence of HCC was doubled in the presence of overweight (15%) and obesity (15%)
compared with non-obesity (7%) (P < 0.05). Time to recurrence also decreased significantly. Differences
in mean  standard deviation survival in the overweight (45  3 months) and obese (41  4 months)
groups compared with the non-obese group (58  6 months) did not reach statistical significance.
Conclusions: These findings indicate that BMI is an important surrogate marker for obesity and por-
tends an increased risk for complications and a poorer oncologic outcome following OLT for HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the fifthmost commonmalig-
nancy and the third leading cause of cancer-related mortality
worldwide.1 Moreover, a recent study looking at the Surveillance,
Epidemiology and End Results (SEER) database demonstrated
that incidence rates for HCC have tripled in the last three decades.2
Furthermore, despite advances in medical care, 1-year survival
rates remain under 50% overall.2 Orthotopic liver transplant
(OLT) represents a potentially curative procedure for patients with
tumours not amenable to resection or ablative therapies. Yao et al.
have shown that with the application of Model for End-stage
Liver Disease (MELD) scores for organ allocation, the number of
patients with HCC undergoing transplantation is rising.3
However, according to the United Network for Organ Sharing
(UNOS) website, 16 868 patients are currently listed for a liver
transplant (http://www.unos.org). Therefore, assessing recipient
characteristics that have negative effects on perioperative and
oncologic outcomes is critical to improve results in OLT for HCC.
Over the last decade, obesity has become a pandemic: more
than 1.1 billion people worldwide are estimated to be over-
weight.4,5 Furthermore, over the last decade nearly 54% of
patients undergoing OLT in the USA have been either overweight
or obese.6 Epidemiologic evidence suggests that obesity is associ-
ated with an increased incidence of multiple cancers, including
HCC and pancreatic cancer.7 Mathur et al. recently showed that
increased visceral fat was associated with an inferior oncologic
outcome and decreased survival in patients with pancreatic cancer
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who underwent pancreatoduodenectomy.8,9 Furthermore, obesity
has been associated with increased perioperative morbidity and
mortality in patients undergoing major surgical procedures.10,11
However, there is a paucity of evidence evaluating the impact of
body mass index (BMI), used as a surrogate measure for obesity,
on the occurrence of postoperative complications and oncologic
outcomes in patients with HCC undergoing OLT. This study
hypothesized that BMI is an important surrogate marker for
obesity and portends an increased risk for complications and an
inferior oncologic outcome in patients with HCC undergoing
OLT.
Materials and methods
Approval to conduct this study was obtained from the University
of South Florida Institutional Review Board. From a database of
over 1000 patients who underwent OLT during 1996–2008, 159
patients with a diagnosis of HCC were identified. All transplants
were performed using organs sourced from deceased donors, in
orthotopic fashion, and were conducted in patients with disease
within the Milan Criteria. Immunosuppression consisted of
tacrolimus-based therapy in 90% and cyclosporine-based therapy
in 10% of patients, with or without the addition of mycopheno-
late mofetil. Patients were weaned from prednisone at 3–6
months, except those with autoimmune liver disease. Demo-
graphic data including age, BMI and sex were obtained. Patients
were categorized as non-obese (BMI < 25 kg/m2), overweight
(BMI  25 kg/m2) or obese (BMI  30 kg/m2). Preoperative
MELD scores and biochemical parameters including serum
bilirubin, creatinine and a-fetoprotein levels were documented.
Perioperative parameters including cold and warm ischaemia
times were recorded. Postoperative length of stay (LoS), compli-
cations, recurrences and survival were noted. Furthermore,
tumour characteristics on final pathology were recorded, includ-
ing tumour size and lymphovascular invasion. Additionally,
complications were grouped according to the Clavien–Dindo
system (Grades I–V).12 Briefly, complications of Grades III, IV and
V are life-threatening: Grade III complications require surgical,
radiologic or endoscopic interventions; Grade IV complications
include organ failure that requires intensive care unit (ICU)
management, and Grade V complications result in patient death.
Statistical analysis
Statistical analyses were performed using Sigma Stat Version 4.0
(Jandel Corp., San Jose, CA, USA). Data were expressed as the
median or as the mean standard deviation (SD) as appropriate.
Data were analysed using analysis of variance (anova), Student’s
t-test and Fisher’s exact test, as appropriate. Survival analyses
were performed using Kaplan–Meier methods. Significance was
accepted with 95% confidence.
Results
Patient demographic data are depicted in Table 1. Of the 159
patients, 47 were non-obese (BMI < 25 kg/m2), 112 were over-
weight (BMI  25 kg/m2) and 58 were obese (BMI  30 kg/m2).
The average age was 55 years and the majority (91%) of patients
were male. Importantly, no differences in patient race were found
across the three groups. The aetiology of HCC is depicted in
Table 2. Hepatitis C was the most common aetiology. No differ-
ences existed among the three groups with respect to aetiology.
Serum biochemical parameters are shown in Table 3. No differ-
ences existed in serum bilirubin, serum creatinine or serum
a-fetoprotein levels across the three groups. Preoperative mean
SDMELD scores did not differ among non-obese, overweight and
obese patients (17 8, 18 7 and 19 7, respectively; P > 0.05).
Table 1 Demographic data for patients undergoing orthotopic liver
transplantation for hepatocellular carcinoma
BMI <
25 kg/m2
BMI 
25 kg/m2
BMI 
30 kg/m2
Patients, n 47 112 58
BMI, kg/m2, mean  SD 23  2 31  4a 34  3a
Age, years, mean  SD 55  7 55  7 55  8
Male gender 87% 92% 91%
White 63% 76% 83%
African-American 10% 5% 4%
Hispanic 20% 18% 13%
Asian 3% 0% 0%
aP < 0.05 versus patients with BMI of <25 kg/m2.
BMI, body mass index; SD, standard deviation.
Table 2 Aetiology of hepatocellular carcinoma in patients undergo-
ing orthotopic liver transplantation
BMI <
25 kg/m2
BMI 
25 kg/m2
BMI 
30 kg/m2
Hepatitis B 5% 2% 0%
Hepatitis C 46% 46% 36%
Laennec's cirrhosis 5% 10% 11%
Hepatitis C + Laennec's cirrhosis 37% 27% 30%
Non-alcoholic steatohepatitis 0% 5% 9%
Cryptogenic steatohepatitis 7% 4% 4%
Other 0% 8% 10%
BMI, body mass index.
Table 3 Serum biochemical parameters in patients undergoing
orthotopic liver transplantation for hepatocellular carcinoma
Serum biochemistries BMI <
25 kg/m2
BMI 
25 kg/m2
BMI 
30 kg/m2
Serum bilirubin, mg/dl,
mean  SD
4  7 5  8 7  10
Serum creatinine, mg/dl,
mean  SD
1.0  1.1 1.0  0.1 1.0  0.5
a-fetoprotein level, U/l,
mean  SD
41  54 167  381 162  281
BMI, body mass index; SD, standard deviation.
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Similarly, cold ischaemia time (437  166 min, 461  168 min
and 455  187 min, respectively; P > 0.05) and warm ischaemia
time (43  9 min, 42  10 min and 42  11 min, respectively;
P > 0.05) did not differ statistically significantly among the non-
obese, overweight and obese groups. Data from explant pathology
evaluation with respect to tumour size (3.1  2.0 cm, 2.8 
1.4 cm and 2.7  1.0 cm, respectively; P > 0.05), lymphatic inva-
sion (3%, 2% and 2%, respectively) and vascular invasion (7%,
9% and 11%, respectively) did not differ among the non-obese,
overweight and obese groups. Furthermore, tumour burden did
not differ among the non-obese, overweight and obese groups
(1.6  1.0, 2.2  2.0 and 2.4  2.0, respectively; P > 0.05). Rates
of preoperative locoregional therapy (LRT) were also similar
among the three groups. Among non-obese patients, 70% under-
went LRT [64% transarterial chemoembolization (TACE), 6%
radiofrequency ablation (RFA)]; among overweight patients, 62%
underwent LRT (58% TACE, 4% RFA) and among obese patients,
55% underwent LRT (48% TACE, 7% RFA). Postoperative LoS is
shown in Fig. 1. Length of stay was significantly greater in obese
patients than in non-obese patients (P < 0.05). Incidences of
Clavien–Dindo Grade I–V complications are presented in Table 4.
There was an increased incidence of life-threatening complica-
tions (Grades III–V) (Fig. 2) in both overweight (58%) and obese
(70%) patients compared with non-obese patients (41%) (P <
0.05). Rates of 90-day mortality were 3% in non-obese patients (n
= 2 of sepsis), 5% in overweight patients (n = 2 of cardiac events,
n = 3 of sepsis), and 4% in obese patients (n = 1 of cardiac events,
n = 1 of sepsis). Additionally, primary graft non-function rates
were 2% in non-obese, 4% in overweight and 3% in obese patients
(P > 0.05). Percentages of recurrence of HCC and months to
recurrence are demonstrated in Figs 3 and 4, respectively. Over-
weight and obesity deleteriously affected both of these parameters
compared with outcomes in non-obese patients. Furthermore,
recurrences occurred in the transplanted allograft in 33% of non-
obese, 50% of overweight and 29% of obese patients (P > 0.05).
Survival is depicted in Fig. 5. Despite a trend towards decreased
survival in overweight (45  3 months) and obese (41  4
months) compared with non-obese (58  6 months) patients,
differences did not achieve statistical significance.
Discussion
Obesity has been shown to be associated with increased morbidity
and mortality following major abdominal procedures.10,11 The
present group has previously shown that visceral fat infiltration is
associated with inferior oncologic outcomes following pancrea-
toduodenectomy for pancreatic adenocarcinoma.8,9 However, the
utility of BMI as a surrogate marker for obesity in determining
oncologic outcomes following OLT for HCC has not been
reported in the literature. This study demonstrates that obesity is
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Figure 1 Length of stay in patients undergoing orthotopic liver trans-
plantation for hepatocellular carcinoma, according to body mass
index (BMI). *P < 0.05 versus BMI < 25 kg/m2
Table 4 Incidences of Clavien–Dindo complications in patients
undergoing orthotopic liver transplantation for hepatocellular
carcinoma
BMI < 25 kg/m2 BMI  25 kg/m2 BMI  30 kg/m2
Grade I 5% 4% 2%
Grade II 21% 9% 4%
Grade III 18% 38%a 45%a
Grade IV 18% 15% 21%
Grade V 3% 5% 4%
aP < 0.05 versus patients with BMI of <25 kg/m2.
BMI, body mass index.
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Figure 2 Incidences of complications (Clavien–Dindo Grades III–V)
in patients undergoing orthotopic liver transplantation for hepatocel-
lular carcinoma, according to body mass index (BMI). *P < 0.05
versus BMI < 25 kg/m2
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a predictor of poorer oncologic outcomes. Specifically, these data
show that a BMI of25 kg/m2 and, particularly, a BMI of30 kg/
m2, is associated with an increased incidence of life-threatening
complications and that obesity is associated with an increased
LoS. Furthermore, the study demonstrates that the incidence of
HCC recurrence is doubled in overweight and obese patients.
Importantly, for those with a BMI of 25 kg/m2, the time to
recurrence of HCC after OLT is also decreased significantly.
Therefore, the present authors believe that the negative impact of
recipient obesity on OLT for HCC results in increased morbidity
and an inferior oncologic outcome; recipient BMI should be taken
into consideration in future policies for the allocation of livers to
patients with HCC.
Recipient demographics are an important predictor of out-
comes following liver transplant. In the present study, recipient
age and sex were similar among the three groups of patients. Nair
et al. recently demonstrated that African-American andAsian eth-
nicities are independent predictors of decreased graft survival and
patient survival.13 Patient race did not differ across the groups in
the present study, although the proportion of Hispanic patients
treated at this centre is larger than the national average. However,
Hispanic race is not associated with poorer outcomes following
liver transplantation.13 As expected the most common aetiology
for liver failure was hepatitis C. This trend is similar to nationwide
trends in the aetiology of liver failure in transplant recipients.6 The
three groups of patients in the present study did not differ with
respect to aetiology of HCC. Interestingly, obese patients were
found to have an increased incidence of non-alcoholic steatohepa-
titis (NASH) compared with non-obese patients, but this trend
did not achieve statistical significance. However, larger studies
looking at nearly 18 000 patients have demonstrated that severe
(BMI  35 kg/m2) and morbid (BMI  40 kg/m2) obesity are
particularly associated with statistically significantly increased
incidences of cryptogenic steatohepatitis and NASH.13 The
present data support this finding, but the sample size in the
present study was too small to allow the adequate classification of
patients into severely obese and morbidly obese groups.
Biochemical recipient characteristics that have been shown to
predict survival include serum bilirubin and serum creatinine.
Thuluvath et al. demonstrated that increased bilirubin and serum
creatinine are independent pre-transplant predictors of decreased
survival at both the 1-month and 1-year time-points after OLT.14
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Figure 3 Incidences of recurrence in patients undergoing orthotopic
liver transplantation for hepatocellular carcinoma, according to body
mass index (BMI). *P < 0.05 versus BMI < 25 kg/m2
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Figure 4 Months to recurrence in patients undergoing orthotopic
liver transplantation for hepatocellular carcinoma, according to body
mass index (BMI). *P < 0.05 versus BMI < 25 kg/m2
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Figure 5 Survival in patients undergoing orthotopic liver transplan-
tation for hepatocellular carcinoma. BMI, body mass index
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The present study demonstrated no differences among the three
groups in either of these pre-transplant parameters. Further-
more, no statistically significant differences in preoperative
a-fetoprotein levels were found among the three groups.
Both cold and warm ischaemia times are important parameters
that determine graft and patient survival. No differences in cold
ischaemia time were noted across the three groups. More impor-
tantly, no differences were noted in warm ischaemia times. This
would suggest that transplanting a liver into an obese individual is
a technically feasible operation and is not associated with pro-
longed warm ischaemia time. This belief is supported by Nair
et al., who demonstrated in a group of 121 patients that intraop-
erative complications and intraoperative transfusion require-
ments were similar in obese and non-obese patients.15 Therefore,
concerns based on the technical difficulty of the operation should
not deter OLT in obese patients.
Morbidity following major abdominal surgery has been found
to be increased in patients with increasing BMI.10 This theory has
been supported in the liver transplant literature. Keeffe et al. 16 and
Sawyer et al. 17 independently demonstrated that morbidity
increases in obese patients following OLT. Sawyer et al.17 noted an
increase in wound infection rates to 20% in obese patients com-
pared with 4% in non-obese patients and an increased incidence
of multi-system organ failure in obese (15%) compared with non-
obese (2%) recipients. However, Braunfeld et al. reported that
obese patients did not have an increased incidence of postopera-
tive complications or LoS.18 However, their study included a
cohort of only 40 obese patients.18 A larger single-institution study
reported by Schaeffer et al., evaluating BMI-related outcomes in
167 liver transplants, noted that obesity increased the incidence of
Clavien–Dindo Grade III complications, including wound dehis-
cences and ventral hernias.19 The present data support the theory
that obesity results in an increased incidence of postoperative
complications. The current study shows that complications
which result in surgical, radiologic or endoscopic interventions
(Clavien–Dindo Grade III) were increased in patients who
were overweight or obese. Furthermore, the percentage of life-
threatening complications was increased in both the overweight
and obese groups in comparison with the non-obese group.
Although postoperative complications after negative-margin (R0)
resections for intra-abdominal malignancies have historically
been related to increased cancer recurrence postoperatively,
neither single-institution studies nor systematic reviews have
identified this as a significant risk factor for recurrence after OLT
for HCC.20,21 This is possibly because unlike other contexts follow-
ing surgery for intraoperative malignancies in which a Clavien–
Dindo Grade III complication would result in an increased
recurrence by an immunosuppressive mechanism, post-OLT
patients are already immunosuppressed.
The incidence of primary graft non-function has been reported
to be increased in morbid obesity.6 The present data on outcomes
in overweight and obese patients do not substantiate this finding.
The incidence of primary graft non-function in non-obese
patients did not differ statistically from that in the overweight and
obese patient groups. Importantly, Nair et al. also demonstrated
that the increase in primary graft non-function did not reach
statistical significance in obese patients (BMI 30–39 kg/m2). Fur-
thermore, as expected, these increased complications resulted in
an increased LoS in obese patients. This is also supported by
previous findings reported in the literature: the Johns Hopkins
group noted that increasing BMI was associated with an increased
LoS and increased hospital costs.15 This is important because it
represents an increased resource utilization by overweight and
obese recipients of liver transplants.
Early postoperative mortality was infrequent (4%) in the
present study and was not affected by increasing BMI. Specifically,
67% (n = 5) of patient deaths occurred as a result of bacterial
sepsis in the immediate postoperative period. The remaining 33%
(n = 2) of patient deaths occurred secondary to cardiovascular
events and one patient suffered an intraoperative cardiac arrest.
This is supported by Braunfeld et al., who noted no difference in
early mortality between non-obese and obese patients.18 However,
both the present study and that reported by Braunfeld et al.18
included a limited number of patients in the obese group and
therefore these data should be interpreted with caution. As noted
previously, major abdominal procedures have been shown to
result in increased mortality in patients who are obese.10,11 Further
studies in larger cohorts of patients are required to identify
whether early postoperative mortality is indeed unchanged in
patients undergoing OLT in the setting of obesity.
Since the institution of the Milan Criteria in 1996,22 with the
demonstration of an acceptable recurrence-free survival in
patients with HCC undergoing OLT, enthusiasm for liver trans-
plantation in patients with HCC has increased. In a large UNOS
study looking at 985 patients with HCC, Yao et al. noted a recur-
rence rate of only 7.6%.3 The present study noted a similar recur-
rence rate of 7% in the non-obese group. However, it also reports
a novel finding of the doubling of recurrence rates in both over-
weight and obese patients following OLT for HCC. Importantly,
this increase was statistically significant. Furthermore, time to
recurrence was significantly decreased in both these groups com-
pared with the non-obese patient group. With respect to patterns
of recurrence, Marsh et al. demonstrated that up to 35% of recur-
rences occur within the transplanted liver itself.23 The present
study demonstrates a similar percentage (42%) of recurrences
occurring in the liver following OLT for HCC. Patterns of recur-
rence were not influenced by BMI.
Factors influencing recurrence rates include tumour pathology
and the provision of LRT prior to liver transplantation.24 With
respect to tumour pathology, specifically tumour size and vascular
invasion have been shown to increase the incidence of recurrence
of HCC. There were no differences in either tumour size or vas-
cular involvement among the groups in the present study. Iwatsuki
and colleagues demonstrated that lymphatic involvement is a sig-
nificant negative predictor of survival following OLT for HCC.25
No differences were noted in lymphatic involvement between the
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non-obese and overweight or obese groups in the current study.
Furthermore, with respect to LRT, Yao et al. suggested that
patients who received preoperative LRT have a potential survival
advantage.24 No differences according to the administration of
preoperative LRT emerged among patient groups in the present
study. This lack of differences in parameters that are known to
influence oncologic outcomes further consolidates the potential
role of increased adiposity in promoting recurrence.
The effects of fatty infiltration of the liver and its progression to
NASH and subsequently HCC are well described in the literature.
However, it is important to note that the majority of recurrences
following OLT for HCC are extrahepatic, as shown in both the
present study and that by Marsh et al.23 These recurrences are
influenced by the systemic milieu of the patient. Obesity is
believed to result in a proinflammatory and protumorogenic
milieu. This effect is mediated through a dysfunctional produc-
tion of adipose-derived adipokines (leptin and adiponectin),
cytokines and chemokines, which are collectively referred to as
adipocytokines.26,27 Leptin, which is elevated in obese humans, has
been shown to increase proliferation and suppress apoptosis in
colorectal and pancreatic cancer cell lines.28 In addition, leptin
increases cell invasion and the induction of leptin receptors can
upregulate expression of angiogenic factors, including vascular
endothelial growth factor.29,30 However, even more significant is
evidence demonstrating a direct effect of leptin on HCC. Both
short and long isoforms of leptin receptors have been observed in
HCC cells at greater concentrations than in other tissues, suggest-
ing that leptin may be involved in HCC.31 Furthermore, Saxena
et al. demonstrated that leptin promotes HCC growth, invasive-
ness and migration and implicated the JAK/STAT pathway as a
critical mediator of leptin action.31 These findings were independ-
ently confirmed by Chen et al.32 Ribatti’s group showed a corre-
lation with leptin and increased angiogenesis in HCC.33 Further,
delineation of the mechanistic pathway of leptin’s effects on HCC
were described by Stefanou et al.,34 who showed that leptin could
affect HCC progression and invasion through its interaction
with cytokines and matrix metalloproteinases (MMPs) in the
tumorigenic microenvironment. The second most predominant
adipokine, adiponectin, is downregulated in the obese state. The
significance of this adipokine is underscored by the fact that adi-
ponectin in vitro inhibits leptin-induced cell proliferation, migra-
tion and invasiveness of HCC cells.35 Therefore, the decrease in
adiponectin coupled with the increase in leptin, in the setting of
obesity, synergistically enhances HCC proliferation, migration
and invasiveness. Therefore, the presence of an obesity-induced
protumorogenic systemic milieu may result in increased tumour
growth and migration of occult microscopic extrahepatic metas-
tases present at the time of liver transplantation. This may account
for the earlier occurrence and increased incidence of recurrence of
HCC in the setting of obesity following OLT.
Increasing BMI has been shown to result in decreased survival
in both lung and renal transplant recipients.36,37 However,
the effects of obesity on survival following OLT have been
contentious. Several single-institution reports have noted that
BMI of 30 kg/m2 is not associated with a decrease in
survival.16–18 However, two large recent UNOS studies suggested
otherwise. One study looking at 18 172 patients demonstrated
decreased survival in severely obese (BMI  35 kg/m2) and mor-
bidly obese (BMI 40 kg/m2) patients.6 Furthermore, the second
study, which looked at outcomes in 38 876 patients, noted that
BMI of 35 kg/m2 is a significant predictor of negative outcomes
at both the 1-month and 1-year time-points following liver trans-
plant.14 The present data demonstrate a trend towards decreased
survival in both overweight and obese patients. However, the
small sample size in the present study prevented the elucidation of
differences in survival between patients who were severely (BMI
 35 kg/m2) and morbidly (BMI  40 kg/m2) obese. Therefore,
the present study’s lack of statistical significance with respect to
survival may be secondary to a type II error caused by the sample
size in comparison with those of the studies looking at UNOS
data. Further cohort studies with larger sample sizes are necessary
to further evaluate survival in HCC in the setting of obesity.
In summary, in patients with HCC undergoing OLT, obesity
results in an increased LoS and a higher risk for life-threatening
complications. Furthermore, it portends an earlier recurrence of
HCC; this represents a novel finding not previously reported.
Therefore, it is concluded that BMI represents an important prog-
nostic marker for obesity and portends an increased risk for com-
plications and a poorer oncologic outcome following OLT for
HCC. Further studies corroborating these data are needed to
determine whether recipient BMI should be taken into considera-
tion in future policies for the allocation of livers to patients with
HCC.
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